Trial Bank
57 trials match
Observational studies (…) are hidden. Tick 'Include observational studies' to show them.
- LTS18002: A study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosis
MSRelapsing MSPhase 3Not yet recruiting
frexalimab · Sanofi-Aventis Recherche & Developpement · 2027 · 37 participants
- LTS17043: A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
tolebrutinib · Sanofi-Aventis Recherche & Developpement · 2024 · 1,405 participants
- FENhance: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
MSRelapsing MSPhase 3Running, not recruiting
fenebrutinib, teriflunomide · Hoffmann-La Roche · 2021 · 746 participants
- FENhance 2: Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
MSRelapsing MSPhase 3Running, not recruiting
fenebrutinib, teriflunomide · Hoffmann-La Roche · 2021 · 751 participants
- CLOU064C12301: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
MSRelapsing and progressivePhase 3Running, not recruiting
remibrutinib · Novartis Pharmaceuticals · 2021 · 1,000 participants
- CLOU064C12302: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
MSRelapsing and progressivePhase 3Running, not recruiting
remibrutinib · Novartis Pharmaceuticals · 2021 · 1,007 participants
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
MSRelapsing and progressivePhase 3Running, not recruiting
tolebrutinib · Sanofi · 2024 · 2,500 participants
- FREXALT: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
MSRelapsing MSPhase 3Running, not recruiting
charcoal, activated, cholestyramine, frexalimab · Sanofi · 2023 · 1,655 participants
- DESIRE MS: A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
MSRelapsing and progressivePhase 3Recruiting
dimethyl fumarate, diroximel fumarate, glatiramer acetate +3 · University Hospital, Montpellier · 2026 · 250 participants
- STOP-I-SEP: Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
MSProgressive MSPhase 3Running, not recruiting
azathioprine, cyclophosphamide anhydrous, dimethyl fumarate +9 · Rennes University Hospital · 2019 · 250 participants
- STHENOS: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
MSRelapsing MSPhase 3Completed
ofatumumab · Novartis Pharmaceuticals · 2021 · 185 participants
- TERI-PK: Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
MSRelapsing MSPhase 4Completed
teriflunomide · Sanofi · 2020 · 82 participants
- GEMINI 1: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
MSRelapsing MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 974 participants
- GEMINI 2: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
MSRelapsing MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 899 participants
- Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 1): Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
MSRelapsing and progressivePhase 3Terminated
evobrutinib · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 2020 · 1,124 participants
- OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
MSRelapsing and progressivePhase 3Completed
ponesimod · Actelion · 2015 · 1,133 participants
- Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 2): Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
MSRelapsing and progressivePhase 3Terminated
evobrutinib · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 2020 · 1,166 participants
- Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
MSRelapsing MSPhase 2Completed
Biocad · 2019 · 271 participants
- TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
MSRelapsing MSPhase 3Completed
teriflunomide · Genzyme, a Sanofi Company · 2014 · 166 participants
- TWINS: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
MSRelapsing MSPhase 3Not yet recruiting
dimethyl fumarate, diroximel fumarate, glatiramer acetate +4 · University Hospital, Strasbourg, France · 2025 · 200 participants
- MIRANTIBUS: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
MSRelapsing MSPhase 3Completed
Biocad · 2021 · 336 participants
- AMA-VACC: Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
MSRelapsing and progressivePhase 4Completed
elasomeran, siponimod, tozinameran · Novartis Pharmaceuticals · 2021 · 41 participants
- SAFE: To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
MSRelapsing MSPhase 4Completed
teriflunomide · Sanofi · 2019 · 121 participants
- TERICIS: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
MSEarly (CIS/RIS)Phase 3Completed
teriflunomide · Centre Hospitalier Universitaire de Nice · 2015 · 5 participants
- TERIS: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
MSEarly (CIS/RIS)Phase 3Completed
teriflunomide · Centre Hospitalier Universitaire de Nice · 2017 · 125 participants
- Main study: switch sub-study: switch-jcv
MSRelapsing MSPhase 4Completed
teriflunomide · Providence Health & Services · 2013 · 55 participants
- Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
MSRelapsing MSPhase 4Completed
teriflunomide · Jan Lycke · 2019 · 12 participants
- ULTIMATE II: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
MSRelapsing MSPhase 3Completed
ublituximab · TG Therapeutics, Inc. · 2017 · 545 participants
- ULTIMATE 1: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
MSRelapsing MSPhase 3Completed
ublituximab · TG Therapeutics, Inc. · 2017 · 549 participants
- ASCLEPIOS II: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
MSRelapsing and progressivePhase 3Completed
ofatumumab · Novartis Pharmaceuticals · 2016 · 955 participants
- ASCLEPIOS I: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
MSRelapsing and progressivePhase 3Completed
ofatumumab · Novartis Pharmaceuticals · 2016 · 930 participants
- TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
MSEarly (CIS/RIS)Phase 3Completed
teriflunomide · Sanofi · 2008 · 618 participants
- Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
MSRelapsing MSPhase 3Completed
teriflunomide · Sanofi · 2006 · 742 participants
- TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
MSRelapsing MSPhase 4Completed
teriflunomide · Sanofi · 2013 · 1,001 participants
- TOWER: An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
MSRelapsing MSPhase 3Completed
teriflunomide · Sanofi · 2008 · 1,169 participants
- TENERE: A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
MSRelapsing MSPhase 3Completed
teriflunomide · Sanofi · 2009 · 324 participants
- TERIVA: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
MSRelapsing MSPhase 2Completed
teriflunomide · Sanofi · 2011 · 128 participants
- Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
MSRelapsing and progressivePhase 2Completed
teriflunomide · Sanofi · 2002 · 147 participants
- TERI-DYNAMIC: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
MSRelapsing MSPhase 3Completed
charcoal, activated, cholestyramine, teriflunomide · Sanofi · 2013 · 70 participants
- A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
MSMS (type not specified)Phase 1Completed
cholestyramine, teriflunomide · Sanofi · 2014 · 12 participants
- TERACLES: Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
MSRelapsing MSPhase 3Terminated
interferon beta, teriflunomide · Sanofi · 2011 · 534 participants
- TEMSO: Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
MSRelapsing and progressivePhase 3Completed
teriflunomide · Sanofi · 2004 · 1,088 participants
- Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
MSMS (type not specified)Phase 2Completed
glatiramer acetate, interferon beta-1a, teriflunomide · Sanofi · 2007 · 182 participants
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
MSMS (type not specified)Phase 2Completed
glatiramer acetate, teriflunomide · Sanofi · 2007 · 123 participants
- Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
MSMS (type not specified)Phase 2Completed
interferon beta-1a, teriflunomide · Sanofi · 2007 · 118 participants
- Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
MSMS (type not specified)Phase 2Completed
teriflunomide · Sanofi · 2001 · 179 participants
- TERI-DYNAMIC: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
MSRelapsing MSPhase 3Completed
teriflunomide · Genzyme Corporation · 2013 · 68 participants
- TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
MSRelapsing MSPhase 4Completed
teriflunomide · Genzyme Corporation · 2013 · 1,000 participants
- TERICIS: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long-term extension period.
MSEarly (CIS/RIS)Phase 3Completed
teriflunomide · CHU de Nice · 2015 · 12 participants
- nd: nd
MSRelapsing MSPhase 4Terminated
teriflunomide · UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI · 2018 · 30 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error